ABOUT BIOMÉRIEUX/NEPHROCHECK
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics for more than 50 years, bioMérieux is present in more than 150 countries through 43 subsidiaries and a large network of distributors. In 2017, revenues reached €2,288 million, with over 90% of international sales. bioMérieux owns and licenses the NEPHROCHECK® test. NEPHROCHECK® received 510(k)-clearance through the FDA’s de novo classification and is CE-marked and available in Europe. For more information on the NEPHROCHECK® test visit www.nephrocheck.com.